Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, that specializes in the research, development, and commercialization of biologics, particularly in the fields of oncology and autoimmune diseases. Founded in 2010, the company offers HLX01, a monoclonal antibody biosimilar of rituximab for treating non-Hodgkin lymphoma, and is advancing several other products through regulatory reviews. Currently, Henlius has approximately 20 clinical studies underway for a diverse portfolio that includes 10 products and 8 combination therapies. The company is also involved in collaborations to develop treatments for COVID-19 and eye diseases, such as wet age-related macular degeneration. Henlius operates both domestically in China and internationally, with a focus on providing affordable and innovative biologics. It is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals.
Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, that specializes in the research, development, and commercialization of biologics, particularly in the fields of oncology and autoimmune diseases. Founded in 2010, the company offers HLX01, a monoclonal antibody biosimilar of rituximab for treating non-Hodgkin lymphoma, and is advancing several other products through regulatory reviews. Currently, Henlius has approximately 20 clinical studies underway for a diverse portfolio that includes 10 products and 8 combination therapies. The company is also involved in collaborations to develop treatments for COVID-19 and eye diseases, such as wet age-related macular degeneration. Henlius operates both domestically in China and internationally, with a focus on providing affordable and innovative biologics. It is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.